A new database will collect information from clinicians about COVID-19-related neurological symptoms, complications, and outcomes as well as COVID-19 effects on pre-existing neurological conditions. The COVID-19 Neuro Databank/Biobank, dubbed “NeuroCOVID,” was created by the National Institutes of Health (NIH) and will be maintained by NYU Langone Health.
FDA Approves PANZYGA® for the Treatment of Adults with CIDP
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA® to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP).
Should Cannabinoids be Recommended for Painful PN?
When asked whether or not cannabinoids should be recommended for a patient with painful neuropathy, two expert physicians with opposing viewpoints for treating neuropathic and chronic pain debated the risks and benefits of the use of cannabinoids.
A new study out of Columbia University is looking to identify how one agent causes nerve degeneration that may lead to the development of the first drugs to prevent peripheral neuropathy and identify people who may be at greatest risk of developing the condition.